← All trials
NCT02459457
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2015
- Primary completion
- Aug 1, 2019
- Completion date
- Dec 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 321
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Fudan UniversityLead sponsor
- Fudan UniversityReponsible party - principal investigator
- Wuxi No. 4 People's HospitalCollaborator
- Jiangxi Provincial Cancer HospitalCollaborator
- Xiamen UniversityCollaborator
- Gansu Provincial HospitalCollaborator
- Fudan UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Nanjing Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.